Literature DB >> 30423408

YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma.

Li Zhong1, Dan Liao1, Meifang Zhang1, Cuiling Zeng1, Xinchun Li1, Ruhua Zhang1, Haiqing Ma2, Tiebang Kang3.   

Abstract

N6-methyladenosin (m6A) is one of the most pervasive modification of mRNA in eukaryotes and the m6A methyltransferases and demethylases play critical roles in many types of cancer. However the role of m6A-binding proteins in cancer remains elusive. Here we report that the down-regulation of YTHDF2 was specifically induced by hypoxia in hepatocellular carcinoma (HCC) cells, and that overexpression of YTHDF2 suppressed cell proliferation, tumor growth and activation of MEK and ERK in HCC cells. Mechanistically, YTHDF2 directly bound the m6A modification site of EGFR 3'-UTR to promote the degradation of EGFR mRNA in HCC cells. This is the first report showing that YTHDF2 may act as a tumor suppressor to repress cell proliferation and growth via destabilizing the EGFR mRNA in HCC.
Copyright © 2018 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EGFR; ERK; HCC; YTHDF2; mRNA

Mesh:

Substances:

Year:  2018        PMID: 30423408     DOI: 10.1016/j.canlet.2018.11.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  117 in total

1.  N 6-Methyladenosine modification of hepatitis B and C viral RNAs attenuates host innate immunity via RIG-I signaling.

Authors:  Geon-Woo Kim; Hasan Imam; Mohsin Khan; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2020-07-27       Impact factor: 5.157

Review 2.  N6-methyladenine RNA modification and cancer.

Authors:  Jun Yang; Junwen Chen; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

3.  3'untranslated regions of tumor suppressor genes evolved specific features to favor cancer resistance.

Authors:  Dan Huang; Xiansong Wang; Ziheng Huang; Yingzhi Liu; Xiaodong Liu; Tony Gin; Sunny Hei Wong; Jun Yu; Lin Zhang; Matthew Tak Vai Chan; Huarong Chen; William Ka Kei Wu
Journal:  Oncogene       Date:  2022-05-06       Impact factor: 9.867

Review 4.  RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy.

Authors:  Subhadra Kumari; Santosh Kumar; Srinivasan Muthuswamy
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-07       Impact factor: 4.553

Review 5.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.

Authors:  Huilin Huang; Hengyou Weng; Jianjun Chen
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

6.  Long noncoding RNA GAS5-AS1 suppresses growth and metastasis of cervical cancer by increasing GAS5 stability.

Authors:  Xiao Wang; Junjun Zhang; Yan Wang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

Review 7.  The evolving landscape of N6-methyladenosine modification in the tumor microenvironment.

Authors:  Yunru Gu; Xi Wu; Jingxin Zhang; Yuan Fang; Yutian Pan; Yongqian Shu; Pei Ma
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 11.454

8.  METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.

Authors:  Jing He; Mingxia Zhou; Jie Yin; Junhu Wan; Jie Chu; Jinlin Jia; Jinxiu Sheng; Chang Wang; Huiqing Yin; Fucheng He
Journal:  Mol Ther       Date:  2021-01-21       Impact factor: 11.454

9.  Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma.

Authors:  Nobuhiko Nakagawa; Fuminori Sonohara; Katsuhito Tanaka; Yuki Sunagawa; Yoshikuni Inokawa; Hideki Takami; Masamichi Hayashi; Suguru Yamada; Mitsuro Kanda; Chie Tanaka; Goro Nakayama; Masahiko Koike; Yasuhiro Kodera
Journal:  Oncol Lett       Date:  2021-05-19       Impact factor: 2.967

10.  YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A.

Authors:  Ling Hong; Xiaowen Pu; Haili Gan; Lichun Weng; Qingliang Zheng
Journal:  J Cancer       Date:  2021-05-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.